A detailed history of Schonfeld Strategic Advisors LLC transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Schonfeld Strategic Advisors LLC holds 334,107 shares of PBYI stock, worth $948,863. This represents 0.01% of its overall portfolio holdings.

Number of Shares
334,107
Previous 46,604 616.91%
Holding current value
$948,863
Previous $247,000 340.89%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.92 - $5.83 $839,508 - $1.68 Million
287,503 Added 616.91%
334,107 $1.09 Million
Q1 2024

May 15, 2024

BUY
$4.29 - $7.4 $113,878 - $196,433
26,545 Added 132.33%
46,604 $247,000
Q4 2023

Feb 14, 2024

BUY
$2.23 - $4.49 $44,731 - $90,064
20,059 New
20,059 $86,000
Q2 2020

Aug 14, 2020

SELL
$7.01 - $13.24 $123,249 - $232,785
-17,582 Closed
0 $0
Q1 2020

May 15, 2020

SELL
$6.28 - $14.57 $383,745 - $890,314
-61,106 Reduced 77.66%
17,582 $148,000
Q4 2019

Feb 14, 2020

BUY
$6.5 - $10.73 $511,472 - $844,322
78,688 New
78,688 $689,000
Q3 2019

Nov 14, 2019

SELL
$8.75 - $12.85 $124,250 - $182,470
-14,200 Closed
0 $0
Q2 2019

Aug 14, 2019

BUY
$12.3 - $35.76 $51,660 - $150,192
4,200 Added 42.0%
14,200 $180,000
Q1 2019

May 15, 2019

SELL
$20.77 - $42.37 $636,683 - $1.3 Million
-30,654 Reduced 75.4%
10,000 $388,000
Q4 2018

Feb 14, 2019

BUY
$20.07 - $46.7 $709,554 - $1.65 Million
35,354 Added 667.06%
40,654 $827,000
Q3 2018

Nov 14, 2018

BUY
$41.2 - $59.85 $74,160 - $107,730
1,800 Added 51.43%
5,300 $243,000
Q2 2018

Aug 14, 2018

BUY
$48.3 - $68.25 $169,050 - $238,875
3,500 New
3,500 $207,000
Q4 2017

Feb 14, 2018

SELL
$93.85 - $132.45 $1.54 Million - $2.17 Million
-16,365 Closed
0 $0
Q3 2017

Nov 14, 2017

BUY
$72.0 - $119.75 $1.18 Million - $1.96 Million
16,365
16,365 $1.96 Million

Others Institutions Holding PBYI

About PUMA BIOTECHNOLOGY, INC.


  • Ticker PBYI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,556,000
  • Market Cap $129M
  • Description
  • Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...
More about PBYI
Track This Portfolio

Track Schonfeld Strategic Advisors LLC Portfolio

Follow Schonfeld Strategic Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Schonfeld Strategic Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Schonfeld Strategic Advisors LLC with notifications on news.